Award Number:  W81XWH-09-1-0667

TITLE: “Investigating the Role of Indoleamine 2,3- dioxygenase (IDO) in Breast Cancer Metastasis”

PRINCIPAL INVESTIGATOR:  Courtney Smith, Ph.D.

CONTRACTING ORGANIZATION:  Lankenau Institute for Medical Research
Wynnewood, PA 19096

REPORT DATE:  September 2012

TYPE OF REPORT:  Final

PREPARED FOR:  U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland  21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Investigating the Role of Indoleamine 2,3-Dioxygenase (IDO) in Breast Cancer Metastasis

First identified as a mediator of acquired immune tolerance of the ‘foreign’ fetus from maternal immunity, the tryptophan-catabolizing enzyme IDO (indoleamine 2,3-dioxygenase) has since been implicated in tumor escape from the host immune system. Primary tumor growth of the metastatic 4T1 breast cancer model was unaffected in the IDO-deficient mice, however, survival was significantly improved. This provided a basis for our studies exploring the importance of IDO in the metastatic site of the lung. Elevation of the inflammatory cytokine IL-6 was associated with tumor outgrowth in the lungs but was greatly attenuated with the loss of IDO, consistent with the in vitro demonstration that IDO activity markedly potentiates IL-6 production. MDSCs (myeloid derived suppressor cells) exhibited reduced T-cell suppressive activity when isolated from tumor-bearing, IDO-deficient animals that could be rescued by ectopic production of IL-6 in the tumor. IL-6 production could likewise reverse the pulmonary metastasis resistance exhibited by IDO-deficient mice. Interestingly, while there is a clear role of the immune system in lung tumor and metastatic outgrowth, IDO-deficient mice appear to have reduced vascularization in the lung which may partly contribute to reduced tumor formation. Together, these findings genetically validate IDO as a therapeutic target in the settings of metastasis and establish the importance of IDO as a driver of IL-6 production and MDSC function. Furthermore, the correlation of IDO to angiogenesis may be a new insight into the role of this enzyme in cancer.

indoleamine 2,3-dioxygenase, lung metastasis, vascularization, IL-6, myeloid derived suppressor cells, 4T1
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>5</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>9</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>9</td>
</tr>
<tr>
<td>Conclusion</td>
<td>11</td>
</tr>
<tr>
<td>References</td>
<td>12</td>
</tr>
<tr>
<td>Appendices</td>
<td>15</td>
</tr>
</tbody>
</table>
INTRODUCTION:

Treatment of cancer commonly entails surgical resection followed by chemotherapy and radiotherapy, a regimen that results in variable degrees of long-term success. This is in part due to the ability of tumor cells to escape these methods of treatment and restore primary tumor growth and, more importantly, distant metastasis. The majority of cancer related deaths are due to the development of metastatic disease as opposed to primary tumor burden. In human breast cancer, the lungs are the primary site of metastasis followed by bone (1,2). Evidence of metastasis in breast cancer patients is considered a strong negative prognostic factor. Therefore, advances in treatment to reduce metastasis will greatly improve survival in breast cancer.

The finding that there is a synergistic benefit to combining chemotherapy with the indoleamine-2,3-dioxygenase (IDO1) inhibitor 1-methyl-tryptophan (1MT) in preclinical mouse models of breast cancer, (3) suggests a promising new therapeutic approach. IDO1 is the rate-limiting factor in tryptophan catabolism; however, it is not involved in dietary catabolism in the liver, leading researchers to determine an alternative role for this enzyme. The seminal demonstration that 1MT could elicit MHC-restricted T cell-mediated rejection of allogeneic mouse concepti (4,5) established a role for IDO1 in mediating immune tolerance. Studies have also revealed a pathophysiological link between IDO1 and cancer with increased levels of IDO1 activity being associated with a variety of different tumors (6,7). The therapeutic potential of targeting IDO1 in conjunction with chemotherapy has been demonstrated in the MMTV-Neu mouse model of breast cancer. The effects of 1MT were found to be greatly enhanced when given in conjunction with the commonly used chemotherapeutic agent paclitaxel (3). Depletion of either CD4+ or CD8+ T-cells in these mice abolished the benefit provided by 1MT indicating the importance of T cell immunity in the antitumor response.

The immunosuppressive function of IDO1 manifests in several manners. Collectively, IDO1 and its metabolites can directly suppress T cells (17-20) and NK cells (21) as well as enhance local Tregs (22). While there are studies showing the protumorigenic capabilities of myeloid derived suppressor cells (MDSCs) (13-16), our publication is the first to show that this population is also be affected by IDO1. Furthermore, IDO1 is produced in response to IFN-γ, an important cytokine modulator of inflammation. It is therefore reasonable to hypothesize that IDO1 not only regulates immune cells but may be regulated by or may regulate cytokine production in the host, resulting in a protumorigenic microenvironment.

To address these questions, we have characterized tumorigenesis in Ido1-/- mice to allow for the study of IDO1 in metastasis. Using an immune competent model, we focused on the role of IDO1 in the immune response to tumors. We have selected the highly metastatic 4T1 breast cancer model which progresses similarly to human breast cancer (10,12). Using this model, we were able to compare the metastatic sites of Ido1-/- and WT mice and evaluate the importance of IDO1 in metastatic outgrowth. Our studies in this model demonstrate that the loss of IDO1 improves survival due to reduced pulmonary metastasis through the reduced immunosuppressive response of the host.
Prior to commencement of all animal-related experiments, IACUC approval to conduct the proposed experiments was obtained. In our first specific aim, we proposed to evaluate IDO1 activity in the lungs of 4T1 tumor-bearing mice and determine the source of its expression. 4T1 cells were orthotopically injected into the mammary fatpad of BALB/c and Ido1-/- mice. After two weeks, palpable tumors were observed and two perpendicular measurements were taken at weekly intervals over a six week period to evaluate primary tumor growth. Initial experiments were performed using a 4T1-derived cell line expressing luciferase (4T1-luc) as we anticipated visualization of metastasis using bioluminescence. However, during our experiments, we found that the luciferase was downregulated in the metastatic cells; whether this reflects the inherent nature of metastatic cells or if it is a result of immune system evasion following intravasation was not investigated. Regardless, the use of the luciferase 4T1 line was deemed unnecessary as the level of bioluminescence underrepresented the amount of metastatic tumor cells. Once we established that the 4T1 luciferase line was no longer necessary, we repeated our results using the parental 4T1 cell line. Both cell lines showed that primary tumors in Ido1-/- mice exhibited a similar growth rate to that observed in the wild-type control (Fig. 1 A-B). However, survival was increased significantly in Ido1-/- hosts compared with WT hosts after challenge with either a 4T1-luciferase–expressing subclone or with parental 4T1 cells, despite an overall shift in the curves (Fig. 1 C-D).

The 4T1 model is a well characterized system to replicate stage IV breast cancer due to the spontaneous metastasis to lungs, liver, lymph node and brain. The highly metastatic nature of 4T1 suggested that the difference in survival, while not related to primary tumor burden, may be a result of disproportionate metastatic burden. Therefore, lung, liver and brain were harvested along with blood and analyzed by the clonogenic assay for metastatic tumors. Metastatic colonies in the brain and liver did not exceed ten per organ and had no statistical difference between WT and Ido1-/- mice (Fig. 2A-B). Interestingly, metastatic colonies in the lung showed that there was less metastatic burden in the lungs of Ido1-/- mice by approximately 10-fold (Fig. 2C). Serum isolated from Ido1-/- and wild-type controls showed similar levels of metastatic cells, indicating that the reduced metastatic spread is not due to decreased tumor cell migration but rather to the reduced ability to establish tumor metastases (Fig. 2C). The observation in lung was further confirmed using both India Ink re-inflation of the lungs and microCT (Fig. 2E). Injection of India Ink into the lungs allowed normal lung tissue to absorb the stain causing metastatic regions to be visualized as white nodules. Similarly, microCT showed normal lung as a dark region while the significantly denser metastatic regions appeared white, further confirming that the improved survival of Ido1-/- mice was due to reduced pulmonary metastasis. Because excision of the primary tumor can alter immune-based effects on metastasis (30), we evaluated the metastatic burden in resected mice. Ido1-/- mice continued to exhibit significant resistance to metastasis development (Fig. 2D), indicating that IDO-mediated support of metastatic development in the lung was not dependent on the presence of the primary tumor. As proposed in the statement of work, these experiments were completed in the first year and a repeat performed in the second year to confirm the original observations. The second study showed the same pattern of reduced metastatic burden and increased survival in Ido1-/- mice providing a final n-value of greater than 20 mice per group. Additionally, in the second year, a smaller cohort of mice injected with parental 4T1 cells were used to negate the possibility that the presence of luciferase affected this study.
The reduction in metastasis observed in the *Ido1-/-* mice suggested that IDO1 is pro-metastatic. We therefore investigated the presence of IDO1 protein in the microenvironment of the lung. Time points were collected at one week intervals from two to six weeks for WT and two to eight weeks for *Ido1-/-* mice. Baseline levels were obtained from non-tumor-bearing mice. In WT mice, early metastases were observed at approximately three to four weeks. By five weeks, there was a substantial metastatic burden, leading to a lethal burden in week six. By comparison, these timepoints were shifted two weeks later for *Ido1-/-* mice requiring timepoints in *Ido1-/-* mice to be extended to eight weeks. No data at seven and eight weeks was available for WT mice as they did not survive past six weeks. Protein IDO1 was measured by immunoprecipitation with αIDO1 and Western blot with a second IDO1 antibody. As expected, *Ido1-/-* mice did not express any IDO1 protein, however, WT mice had greater levels of IDO1 as metastatic burden increased (Fig. 3A). Using LC/MS/MS to measure the presence of kynurenine, a product of tryptophan catabolism by IDO1, we were able to demonstrate that the IDO1 protein in the lung microenvironment was functionally active, and the level of kynurenine increased directly in relation to the protein (Fig. 3B). This further supported the importance of IDO1 in the lungs for optimal conditions of metastatic outgrowth. These data were collected in a second cohort of mice in year two to increase the n-value to greater than ten mice per group. The data from these figures is presented in our appended Cancer Discovery paper. Cancer Discovery is the flagship journal from AACR that, while still a young journal, has received the prodigious 2011 American Publishers Award for Professional and Scholarly Excellence and is acknowledged as publishing top-rated peer reviewed articles.

Current roadblocks remain in the difficulty of obtaining an IDO1 antibody suitable for immunohistochemistry. Until recently, existing antibodies have not been used on *Ido1-/-* mice and therefore no publications of IDO1 immunohistochemistry have this control. Our lab and others have observed high levels of non-specific staining in *Ido1-/-* samples, suggesting that these antibodies are not suitable for IHC. We are currently collaborating with other researchers at LIMR to develop our own antibody to IDO1. Our previous attempts to generate an antibody against full length protein have been unsuccessful. Therefore, we are now generating antibodies to an IDO peptide located in the deleted region of the *Ido1-/-* mice. These studies are currently underway.

Despite the inability to detect IDO1 by immunohistochemistry, we worked out conditions for staining and discovered an interesting result surrounding the *Ido1-/-* mice. While optimizing the Blood Vessel Staining Kit from Millipore to look for CD31 and von Willebrand’s as proposed in the first aim, we costained with caveolin-1 (cav-1), another marker for blood vessels. The conditions for staining Cav-1 had previously been optimized for immunofluorescence. While we initially were interested in the level of Cav-1 in the metastatic lung, we noticed that there was a difference in the normal controls (Fig. 4C). Immunofluorescent staining of Cav-1 revealed that there are fewer pulmonary vessels in *Ido1-/-* animals by approximately 1.6-fold (Fig. 4). Further analysis of vessel size indicated that there was little difference in the number of large vessels but rather the level of small- to medium-sized vessels had the most dramatic difference (Fig. 4B,D). This was confirmed after analysis using the microCT to analyze previously collected images (Fig. 4A) (additional supplemental videos can be viewed in the Cancer Discovery publication). This discovery may provide an important new function for IDO in metastasis.
The second specific aim was designed to characterize the immune response in the lungs of 4T1 tumor-bearing mice. During the second year, we performed bone marrow chimera experiments. To effectively determine the reconstitution of the irradiated mice, we proposed the use of C.B-17 mice. C.B-17 mice are a congenic strain on a BALB/c background that carries the immunoglobulin heavy chain allele (Igh-1b) found on C57BL6 mice. This provides a marker to determine the level of reconstitution. Our pilot run showed that we have greater than 99% successful reconstitution in our mice. Furthermore we found that the use of C.B-17 mice in place of BALB/c did not affect the rate of lung metastasis as determined by the number of circulating tumor cells and number of pulmonary metastases counted by the colony forming assay (Fig. 5A).

Following the initial pilot experiment, we set up two bone marrow chimera experiments to measure the effects of the immune cells. The first experiment was set up as a clonogenic colony forming assay (Fig. 5B) and the second as a survival study (Fig. 5C). Both experiments resulted in greater metastasis susceptibility of mice with Ido1-/− marrow transplanted into an irradiated Ido1-/− mouse compared to irradiated WT mice receiving WT bone marrow. As these served as our control groups and the data runs counter to our expected results, we were unable to interpret the experimental conditions of transplanting WT mice with Ido1-/− marrow and visa versa. Due to both experiments resulting in the same outcome, we must consider the possibility that Ido1-/− mice are more susceptible to metastasis as a result of irradiation.

While data from the bone marrow chimera experiments were inconclusive, we proceeded to determine which immune cells may be involved in metastasis by focusing on the infiltrating immune cell profile. The profile was evaluated for differences between the WT and Ido1-/− 4T1 tumor-bearing mice by enzymatically dissociating lung tissue to form single cell suspensions for analysis by flow cytometry using the following panel of antibodies: CD45, CD4, CD8, CD3, B220, CD11c, CD11b and Gr1 (Fig. 6). Lung samples were collected at one week intervals between one and five weeks following tumor engraftment (Fig. 6A-E). Between two and three weeks, the immunosuppressive MDSC population, identified here as CD11b+Gr1+, was greatly increased in the WT mice (Fig. 6F). The data collected from these studies represent the percentage of positive cells from each immune cell population out of the entire CD4+ population. The data indicated greater numbers of MDSCs in WT mice. These data parallel previous data in IL-1β knockout mice that showed the same delay in MDSC accumulation (4).

In response to reviewer comments on our manuscript, we provided further supplemental data of the functional effects on MDSCs. In collaboration with the laboratory of Dr. Suzanne Ostrand-Rosenberg, we demonstrated that MDSC-suppressive activity is attenuated in IDO-deficient mice. MDSCs from WT and Ido1-/− mice did not have phenotypic differences based on microscopic evaluation of these cells using hematoxylin and eosin staining (Fig 7A). However, the functional ability to suppress T cells was impaired in MDSCs from these mice as they were less able to suppress both CD4+ and CD8+ T-cells (Fig. 7B-C). Detailed explanations and supplemental information for MDSC phenotyping can be found in the appended Cancer Discovery supplemental figure 3.

The microenvironment of the lung affects the ability of 4T1 tumors to metastasize. Loss of IDO1 reduces tumor metastasis and is accompanied by a shift in the immune cell profile, implicating the immune system in this suppression. Additionally, environmental cues may be altered such that tumor growth is not favored. Due to studies implicating a relationship between cytokines and IDO1, we hypothesized in the third specific aim that the cytokine profile in the lungs of tumor-bearing mice in the Ido1-/− versus the wild-type would be different.
Lung homogenates were evaluated using the Cytometric Bead Array (BD Biosciences) from samples collected at one week intervals from two to five weeks following tumor engraftment from groups of at least four mice each. This array uses amplified fluorescence detection by flow cytometry to detect soluble analytes to provide multiplexed data comparable to a classical ELISA. Initially, lung homogenates were analyzed for a set of cytokines that included IL-2, IL-4, IL-5 and IL-17 to determine differences in cytokines influencing immune cell maturation. Specifically, these cytokines regulate divergence into Th1, Th2 or Th17 cell lineages. It is generally accepted that a Th1 environment suppresses tumor outgrowth while a Th2 environment promotes immune escape. The cytokine profile for Th1/Th2/Th17 showed no measurable levels of these cytokines above the limit of detection (Fig. 8).

This prompted the use of a second panel of cytokines that reflect inflammation in the lung and included IL-6, IL-10, MCP-1, IFN-γ, TNF and IL-12p70. Samples were collected and analyzed similarly to the Th1/Th2/Th17 analysis. MCP-1 and IL-6 showed increased levels during tumor progression in WT mice (Fig. 9A-B). MCP-1 showed higher levels of expression in WT mice starting at two weeks and continuing through six weeks (Fig. 9A). The increase was on average two-fold greater than the Ido1-/- mice. While MCP-1 was increased in Ido1-/- mice, the response was less robust. Similar data was acquired for IL-6 with the difference that increased IL-6 was not observed until four weeks after orthotopic injection at which time there was a two-fold increase (Fig. 9B). At five weeks, IL-6 was on average four-fold higher than the Ido1-/- mice which only had a marginal rise in IL-6 levels. These results collectively demonstrated that Ido1-/- mice have a suppressed inflammatory response to 4T1. Both TNF and IFN-γ showed equal elevations at each time point between WT and Ido1-/- starting at three weeks and continuing through six weeks (Fig. 9C-D). These cytokines are generalized responders to inflammation and may reflect a response to the primary tumor burden or early tumor cell extravasation. There was no upregulation of IL-12p70 or IL-10 in either WT or Ido1-/- mice (Fig. 9E-F).

After identifying IL-6 as a cytokine involved in establishing metastatic progression, we wanted to demonstrate a direct connection with IDO. Due to the difficulty in studying a mouse model, we invoked a cell culture system to provide a clear mechanism to study IDO and IL-6. Using lipopolysaccharide (LPS) to induce IDO activity in the monocytic U937 cells, we observed induction of IL-6 (Fig. 10A). The addition of a competitive IDO-inhibitory compound, MTH-tryptophan, significantly suppressed the observed increase in both IDO activity as well as IL-6 production (Fig. 10B). The effect was confirmed in a second monocytic cell line HL-60 (Fig. 10C). Using HL-60 cells, we successfully knocked down IDO using siRNA-mediated interference (reduced to 90%) and found that IL-6 induction was suppressed (Fig. 10C). These data supported our in vivo studies connecting IDO activity to the elevated production of IL-6.

To connect IL-6 to MDSC activity in vivo, we generated an IL-6 overexpressing 4T1 cell line (4T1-IL-6). Parental 4T1 or the 4T1-IL6 cells were orthotopically injected into WT or Ido1-/- mice. Due to the high levels of IL6 in the primary tumors, the mice succumbed to the primary tumor effects and not pulmonary metastases. We therefore intravenously engrafted both cell lines into WT and Ido1-/- mice and found that the Ido1-/- mice maintained their resistance to pulmonary metastasis formation (tumor burden was 30.4-fold and 31.6-fold lower in Ido1-/- versus WT mice challenged with 4T1 and 4T1-IL6 cells, respectively (Fig. 11A). The metastatic burden in the 4T1-IL6 challenged mice was proportionally increased, indicating that IL-6 is not being produced at saturating levels in the 4T1 injected WT animals. However, comparison of metastatic burden in WT mice injected with parental 4T1 and Ido1-/- mice injected with 4T1-IL6
showed only a 4.8-fold differential. Thus, IL-6 supplementation restored susceptibility of Ido1-/\- mice to pulmonary metastasis development. This also paralleled the effects of the MDSC function from these groups as well (Fig. 11B). While MDSC function was restored proportionally in WT and Ido1-/\- mice with 4T1-IL6 over their 4T1 parental counterparts, the 4T1-IL6 tumor challenged Ido1-/\- mice had MDSCs that were functionally like the 4T1 tumor challenged WT mice. IL-6 and MDSC data can also been viewed in the appended Cancer Discovery publication.

KEY RESEARCH ACCOMPLISHMENTS:

- Found that the improved survival of Ido1-/\- mice is due to reduced pulmonary metastasis
- Confirmed that expression of IDO1 protein is present in the metastatic site of the lung in the orthotopically engrafted 4T1 breast cancer model and correlated with activity as evidenced by increased kynurenine production
- Demonstrated that equal numbers of circulating tumor cells are observed in WT and Ido1-/\- mice suggesting the effect of IDO1 loss and improved survival is due to a decreased adherence, extravasation or metastatic outgrowth
- Determined that the immunosuppressive MDSC population increases more rapidly in WT mice compared to Ido1-/\-, a pattern previously seen in IL-1\beta knockout mice; further showed a functional defect in MDSC function in Ido1-/\- mice
- Found measurable differences in inflammatory cytokine levels between Ido1-/\- mice and the WT counterparts, particularly pertaining to the cytokines IL-6 and MCP-1
- Demonstrated in culture that IDO inhibitors can block production of IL-6 in response to LPS induction and IDO-inhibitory compound MTH-tryptophan
- Overexpressed IL-6 in 4T1 cells to demonstrate that metastatic potential can be restored in Ido1-/\- mice to WT levels
- Implicated IDO in the reduced vascularization of normal lung

REPORTABLE OUTCOMES:

PUBLICATIONS


MEETINGS


   Travel Award/Conference Assistant for Keystone Symposium on Molecular and Cellular Biology of Immune Escape in Cancer, Feb 7-12, 2010, Keystone Resort, Keystone, CO


PERSONNEL:

Courtney Smith
CONCLUSION:

There are over 40,000 deaths each year in the US resulting from the metastatic spread of breast cancer. Based on data from our lab and others, an IND (investigational new drug) application for the IDO1 inhibitor D-1MT was approved and Phase I clinical trials have commenced. Breast cancer is identified in the clinical development plan as one of the high priority disease indications for evaluation in Phase IIA studies that will be used to determine the clinical scenarios best suited for the Phase II/III clinical development of this agent. Our recently published finding that D-1MT treatment in combination with cyclophosphamide chemotherapy significantly improved survival in mice bearing highly malignant 4T1 tumors (9) suggests for the first time that this approach may be applicable to metastatic disease as well.

Using the IDO1-knockout mouse strain, we have been able to genetically establish that IDO1 is important for supporting the development of pulmonary metastases from orthotopic 4T1 tumors. The core goal of the proposed project has been to determine the underlying biological basis for this pro-metastatic effect of IDO1. The data collected from these experiments resulted in the first publication that IDO affects MDSC function by making them less able to suppress both CD4+ and CD8+ T-cells. The high levels of IL-6 and MCP-1 in the metastatic lungs of WT mice further support the role of the IDO in immune system regulation. The presence of IL-6 was correlated with increased metastasis in WT mice while Id1-/- mice had low levels of IL-6 and less metastasis. To directly tie IDO to IL-6 production, we utilized two cell lines that were induced with LPS to produce IDO. This induction resulted in IL-6 production and the addition of an IDO-inhibitor reduced both IDO levels and IL-6. In vivo, we have shown that IDO deficiency not only affects IL-6-dependent, MDSC driven immune escape but also lung vascularization. While models of exogenous IDO overexpression in tumor xenografts have shown enhanced tumor vascularization (26, 27), these studies genetically establish a role for IDO in supporting vascular development under native physiological conditions. The reduced numbers of vessels in IDO1 deficient mice suggest that IDO supports the metastatic dissemination into lung tissue where IDO can readily and significantly be induced during tumor initiation. Future experiments investigating the connection between IDO and vascularization will be critical in understand this cancer target.

The data produced from these studies have elucidated a novel mechanism of action through which IDO1 inhibitors can enhance the antitumor immune response achieved with cyclophosphamide chemotherapy, a frontline agent for the treatment of breast cancer patients. The results of these studies could have immediate bearing on how future clinical trials with IDO1 inhibitory compounds are designed and may lead to the development of more effective strategies for administering IDO1 inhibitors for the treatment of patients with metastatic breast cancer.
REFERENCES:


APPENDICES:

1. Figures 1 to 11.


3. Supplementary Figures 1 to 3.
Figure 1: IDO deficiency delays the development of pulmonary metastases but not primary tumor growth. (A,B) Primary 4T1 tumor growth is unaffected in Ido1/- mice. WT and Ido1/- mice received orthotopic grafts of (A) 4T1-luc (N = 20) or (B) 4T1 (N = 5) cells. Beginning at approximately 14 days, when a palpable tumor mass had become apparent, caliper measurements were made on a weekly basis to calculate primary tumor volumes. The data are plotted as means ± SE. Measurements for WT mice challenged with 4T1 cells at 42 days were not collected due to metastasis-associated mortality in this group. (C,D) Kaplan-Meier survival curves for cohorts of WT and Ido1/- mice following orthotopic engraftment of 1 x 10^4 (C) 4T1-luc (n = 25) or (D) 4T1 (n ≥ 9) tumor cells. Significance was assessed by 2-group log-rank test at P < 0.05. The survival benefit observed in Ido1/- mice was independently replicated at University of Maryland Baltimore County.
Figure 2: *Ido1*-/− mice show reduced pulmonary metastases compared to WT mice. (A-B) *Ido1*-/− mice exhibit no demonstrable resistance to 4T1 brain (A) or liver (B) metastasis formation. At 6 weeks following orthotopic injection of 4T1-luc cells into WT and *Ido1*-/− hosts (N = 5 per group), colony forming assays were performed to assess the relative tumor cell burden in the liver. Individual data points are graphed as a scatter plot on a log scale together with the means ± SE. Because the data are plotted on a log scale, points with a value of 0 are not represented in the scatter plot but were included in computing the means. (C-D) At 5 weeks following (C) orthotopic engraftment of 4T1 cells (n = 6) or (D) orthotopic engraftment of 4T1 cells and resection of the primary tumor at 18 days postengraftment (n ≥ 11), colony forming assays were conducted to assess the relative tumor cell burden in the blood (neat) and lungs (1:1000). Individual data points are graphed on a log scale scatter plot with the means ± SEM and significance assessed by 2-tailed Student t test at P < 0.05 (NS, not significant). (E) Staining of lung with India Ink and axial images from micro-CT scans depicting the difference in pulmonary metastasis burden between WT and *Ido1*-/− mice at 5 weeks following orthotopic 4T1 tumor cell engraftment.
Figure 3: IDO protein and activity correlates with increased 4T1 tumor metastasis. (A) Evaluation of IDO1 protein levels by immunoprecipitation-Western blot analysis of lung tissue lysates from WT and Ido1-/- mice following orthotopic engraftment of 4T1 tumor cells at the time points in weeks indicated above each lane. C. epididymis lysate positive control lane; M, molecular weight marker lane. (B) Evaluation of kynurenine levels by LC/MS-MS-based analysis of homogenized lung samples from WT and Ido1-/- mice following orthotopic engraftment of 4T1 tumor cells at the time points in weeks indicated for each lane. Means ± SEM (n ≥ 6) are graphed with significance relative to baseline determined by one-way ANOVA with Dunn test (*, P<0.05; **, P<0.01).
Figure 4: Vascular density is reduced in the lungs of Idol-/- mice. (A) Volumetric image analysis of tumor and vasculature performed on the 3-D reconstructions of lung micro-CT images. The data are graphed as a scatter plot with the means ± SEM (Δ; fold difference). Significance was determined by two-tailed Student’s t test at P < 0.05. (B) Distribution of pulmonary vessels within specified size ranges. The total number of small (<500 μm²), medium (500-5000 μm²) and large (>5000 μm²) vessels identified within the defined fields evaluated in D are plotted on a bar graph (Δ; fold difference. (C) Immunofluorescent staining of blood vessels with antibody to caveolin 1 (red) and DAPI staining of nuclei (blue) in representative lung tissue specimens from WT and Idol-/- mice. Lung tissue sections from 5 WT and 5 Idol-/- mice were stained with anti-caveolin-1 antibody to visualize blood vessels by immunofluorescence. Four images per tissue section were acquired and area measurements of every blood vessel within each field were recorded using AxioVision Release 4.6 software. (D) All of the area measurements were tallied and plotted sequentially in ascending order from smallest to largest with vessel areas graphed on a log scale. The differential in vessel density apparent from this graph is due almost entirely to a reduced number of medium to small sized vessels in the lungs of Idol-/- mice while the number of large vessels (>5000 μm²) is nearly the same as in the WT mice.
Figure 5: Bone Marrow Chimera Experiments. (A) Lung tissue was homogenized and blood collected 6 weeks following orthotopic engraftment of 4T1 cells into BALB/c and C.B-17 mice. Colony forming assay to measure metastatic spread showed equal metastatic burden in BALB/c mice and C.B-17 mice. (B) Following bone marrow transplant, colony forming assay shows that control experiments run the opposite of expected, with Ido1-/ to Ido1-/ mice having greater metastatic burden compared to WT to WT mice. (C) A small cohort in a survival assay had similar results with WT to WT mice surviving longer than Ido1-/ to Ido1-/ mice, negating the use of either experiment.
Figure 6: MDSCs are elevated early in WT mice. Whole lung tissues from WT and Ido1−/− mice at weekly time intervals were enzymatically digested to single cell suspensions for analysis by flow cytometry. Immune cells were selected by gating on CD45+ cells. Cells were further identified for T-cells (CD4+ and CD8+), B-cells (B220+), macrophages (CD11c+) and the MDSC cell type by Gr1+CD11b+ expression. Immune cell profiles were measured at (A) 1.5 weeks, (B) 2.5 weeks, (C) 3.5 weeks, (D) 4.5 weeks and (E) 5.5 weeks following orthotopic injection. (F) Comparison of MDSCs over time course.
Figure 7: MDSCs from *Ido1*−/− mice are less suppressive. (A) Comparative microscopic images of H&E-stained MDSCs harvested from the blood of WT and *Ido1*−/− mice with primary 4T1 tumors that were not significantly different in size (12.2 ± 1.36 and 11.5 ± 0.4 mm in diameter, respectively). (B) Single cell suspensions of whole lung tissues were prepared at the indicated time points following 4T1 engraftment into WT and *Ido1*−/− mice and evaluated by flow cytometry for MDSC infiltration by gating on CD45+ cells and analyzing the Gr1+ CD11b+ cell population. Means ± SEM are graphed with significance assessed by two-tailed Student’s *t* test at *P* < 0.05. (C) Splenocytes from CD4+ TS1 (left) or CD8+ Clone 4 (right) mice were co-cultured in triplicate with cognate peptide and increasing proportions of 4T1-induced, peripheral blood MDSCs from WT or *Ido1*−/− mice. T cell activation was quantified by uptake of 'H-thymidine and graphed as percent suppression relative to activation in the absence of MDSCs. Significance was assessed by Wilcoxon Rank test at *P* < 0.05. Outcomes are representative of a minimum of 3 independent experiments.
Figure 8: Metastasis does not affect Th1/Th2/Th17 cytokines. Homogenized lung tissue was analyzed for a panel of cytokines using the cytokine bead array. Cytokines are graphed as the average cytokine level in lung of five mice as a factor of time. Data shows mean and SEM. Neither IL-2, IL-4 nor IL-5 showed significant induction in either WT and IDO1/- mice.
Figure 9 Metastasis induces inflammatory cytokines. Homogenized lung tissue was analyzed for a panel of cytokines using the cytokine bead array. Cytokines are graphed as the average cytokine level in lung of five mice as a factor of time. Data shows mean and SEM. (A) MCP-1 levels are induced as early as 3 weeks and continue to elevate beyond that of Ido1-/− mice. (B) IL-6 levels similarly increase and are maximally induced at 6 weeks. (C-D) IFN-γ and TNF levels are induced maximally at 5 weeks in both WT and Ido1-/− mice. (E-F) Neither IL-12p70 nor IL-10 showed significant changes in induction between WT and Ido1-/− mice.
Figure 10: IDO-dependent potentiation of IL6 production. (A) Supernatant from U937 cells stimulated for 24 hours with IFNγ (100 ng/ml) and/or LPS (100 ng/ml) was analyzed for kynurenine and IL6. Results from triplicate plates are plotted as the means ± SEM. Methyl thiohydantoin tryptophan (MTH-Trp, 100 μmol/l) was included during induction where indicated and significance relative to the corresponding induced level without MTH-Trp was determined by two-tailed Student’s t test (**; *P < 0.0001). (B) Supernatant from HL-60 cells stimulated for 24 hours with IFNγ (100 ng/ml) and LPS (100 ng/ml) was analyzed for kynurenine and IL6. Results from duplicate plates are plotted as the means ± SEM. Methyl thiohydantoin tryptophan (MTH-Trp, 100 μmol/l) was included during induction where indicated and significance relative to the corresponding induced level without MTH-Trp was determined by two-tailed Student’s t test (*; *P < 0.05). (C) HL-60 cells treated in triplicate with Ido1-targeting (si-Ido1) or non-targeting (si-Gapdh) siRNAs were stimulated for 24 hours with IFNγ (100 ng/ml) and LPS (100 ng/ml). Pooled cell lysates were analyzed by Western blot analysis for IDO1 and actin (left panel) and individual cell supernatants were analyzed for IL6 (right panel). The IL6 data are plotted as the means ± SEM with the significance of the difference between specific ido1-targeting versus non-targeting results determined by two-tailed Student’s t test (**; **P < 0.0001).
Figure 11: Attenuated MDSC suppressive activity and metastasis development in IDO-deficient mice is rescued by IL6. (A) Splenocytes from CD8\(^+\) Clone 4 transgenic mice were co-cultured with cognate peptide and increasing proportions of 4T1 or 4T1-IL6 tumor-induced MDSCs from WT or Ido1\(^{-/-}\) mice for analysis as in B. Outcomes are representative of 6 independent experiments using TS1, Clone 4, or DO11.10 transgenic T cells. (B) Colony forming assays to assess the relative tumor cell burden in the lungs performed 6 weeks following intravenous injection of 4T1 or 4T1-IL6 cells into WT and Ido1\(^{-/-}\) mice. Results are presented on log scale scatter plot with means ± SEM. Significance was assessed by two-tailed Student’s t test at \(P < 0.05\).
IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development

Courtney Smith, Mee Young Chang, Katherine H. Parker, et al.

Cancer Discovery Published OnlineFirst July 19, 2012.

Updated Version
Access the most recent version of this article at:
doi:10.1158/2159-8290.CD-12-0014

Supplementary Material
Access the most recent supplemental material at:
http://cancerdiscovery.aacrjournals.org/content/suppl/2012/06/18/2159-8290.CD-12-0014.DC1.html

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.
IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development

INTRODUCTION

Inflammatory tissue microenvironments contribute strongly to tumor progression, but due to the complex multifactorial nature of inflammation, there remains limited understanding of specific pathogenic components that might be targeted to effectively treat cancer (1). In this context, the tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) has emerged as an intriguing target implicated in tumoral immune escape (2, 3). IDO-inhibitory compounds have entered clinical trials based on evidence of immune-based antitumor responses in a variety of preclinical models of cancer (4–10). Meanwhile, inadvertent IDO targeting may already be providing benefits in a variety of preclinical models of cancer (4–10). Meanwhile, inadvertent IDO targeting may already be providing benefits in preclinical models of cancer (4–10).

Although results with IDO pathway inhibitors are provocative, the conclusions that can be drawn are inherently limited by drug specificity concerns, especially in the absence of independent genetic validation. Addressing this issue, our studies on the impact of Id01 gene deletion on 7,12-dimethylbenz(a)anthracene/12-O-tetradecanoylphorbol-13-acetate (DMBA/TPA)-elicited skin papillomagenesis established that IDO has an integral tumor-promoting role in the context of phorbol ester–elicited inflammation (12, 13), but interpretation of these results is tempered by the possibility that the chemical exposures in this model may produce anomalies irrelevant to the majority of spontaneous tumors. The lungs present a particularly compelling physiologic context in which to further investigate the role of IDO in tumorigenesis as IDO is known to be highly inducible in this tissue (14, 15), and there is an urgent unmet medical need for effective therapeutic options to treat primary lung tumors and metastases. In this report, we investigated the consequences of IDO loss through genetic ablation in the context of well-established, pulmonary models of oncogenic KRAS-induced adenocarcinoma and orthotopic breast carcinoma metastasis. Our findings reveal previously unappreciated roles for IDO in vascularization and in the production of the proinflammatory cytokine interleukin (IL)-6 that in turn dictates the development of protumorigenic, myeloid-derived suppressor cells (MDSC).

AUTHORS’ AFFILIATIONS

1Lankenau Institute for Medical Research; 2NewLink Genetics Corporation, Wynnewood, Pennsylvania; 3Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, Maryland; 4Department of Biochemistry, Drexel University College of Medicine; 5Department of Pathology, Anatomy, and Cell Biology, 6Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania; and 7Richfield Laboratory of Dermatopathology, Cincinnati, Ohio

Note: Supplementary data for this article are available at Cancer Discovery Online (http://cancerdiscovery.aacrjournals.org/).

C. Smith and M.Y. Chang contributed equally to this study.

Corresponding Authors: Alexander J. Muller and George C. Prendergast, Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood, PA 19096. Phone: 484-476-8034 or 8475; Fax: 484-476-8533; E-mail: mullera@mlhs.org or prendergast@limr.org

doi:10.1158/2159-8290.CD-12-0014

©2012 American Association for Cancer Research.

ABSTRACT

Indoleamine 2,3-dioxygenase (IDO) enzyme inhibitors have entered clinical trials for cancer treatment based on preclinical studies, indicating that they can defeat immune escape and broadly enhance other therapeutic modalities. However, clear genetic evidence of the impact of IDO on tumorigenesis in physiologic models of primary or metastatic disease is lacking. Investigating the impact of Id01 gene disruption in mouse models of oncogenic KRAS-induced lung carcinoma and breast carcinoma–derived pulmonary metastasis, we have found that IDO deficiency resulted in reduced lung tumor burden and improved survival in both models. Micro-computed tomographic (CT) imaging further revealed that the density of the underlying pulmonary blood vessels was significantly reduced in Id01-nullizygous mice. During lung tumor and metastasis outgrowth, interleukin (IL)-6 induction was greatly attenuated in conjunction with the loss of IDO. Biologically, this resulted in a consequential impairment of protumorigenic myeloid-derived suppressor cells (MDSC), as restoration of IL-6 recovered both MDSC suppressor function and metastasis susceptibility in Id01-nullizygous mice. Together, our findings define IDO as a prototypical integrative modifier that bridges inflammation, vascularization, and immune escape to license primary and metastatic tumor outgrowth.

SIGNIFICANCE: This study provides preclinical, genetic proof-of-concept that the immunoregulatory enzyme IDO contributes to autochthonous carcinoma progression and to the creation of a metastatic niche. IDO deficiency in vivo negatively impacted both vascularization and IL-6–dependent, MDSC-driven immune escape, establishing IDO as an overarching factor directing the establishment of a protumorigenic environment. Cancer Discov; 2(8); 1–14. ©2012 AACR.

RESULTS

IDO Deficiency Prolongs the Survival of Mice with Sporadic KrasG12D-Driven Lung Carcinomas

LSL-KrasG12D (Lox-Stop-Lox KrasG12D) transgenic mice develop sporadic focal pulmonary adenocarcinomas following intranasal administration of Cre-expressing adenovirus vector.
Smith et al.

RESEARCH ARTICLE

Figure 1. IDO deficiency extends the survival of mice with KRAS-induced lung adenocarcinomas despite an elevated number of early lesions. A, Kaplan–Meier survival curves for cohorts of Lox-Kras\(^{G12D}\) (n = 23) and \(\text{Ido}1^{-/-}\)Lox-Kras\(^{G12D}\) (n = 14) mice infected with 2.5 × 10\(^7\) plaque-forming units (pfu) of Ad-Cre virus. B, Kaplan–Meier survival curves for cohorts of Lox-Kras\(^{G12D}\) (n = 8) and \(\text{Ido}1^{-/-}\)Lox-Kras\(^{G12D}\) (n = 5) mice infected with 1.25 × 10\(^8\) pfu Ad-Cre virus. Significance for both data sets was assessed by 2-group log-rank test at \(P < 0.05\). C, total lung DNA prepared from 3 mice per time point was analyzed for the presence of the viral Cre gene by real-time PCR at 0, 1, 3, and 7 days postinfection. Relative Cre levels determined from this analysis are plotted as means ± SEM. D, representative hematoxylin and eosin (H&E)-stained sections depicting the observed difference in early lesions between the lungs of Lox-Kras\(^{G12D}\) and \(\text{Ido}1^{-/-}\)Lox-Kras\(^{G12D}\) mice at 6 weeks postinfection. E, quantitative histopathologic assessment of lesion frequency in H&E-stained sections of lung biopsies from Lox-Kras\(^{G12D}\) and \(\text{Ido}1^{-/-}\)Lox-Kras\(^{G12D}\) mice at 6 and 12-week postinfection (n ≥ 5). The number of lesions identifiable under low magnification within a defined region of each specimen are graphed on the scatter plot with the means ± SEM. Significance was determined by 2-tailed Student t test at \(P < 0.05\). NS, not significant.

(Ad-Cre) to activate the latent oncogenic Kras\(^{G12D}\) allele (16). These RAS-induced adenocarcinomas elicit a robust inflammatory response (17) wherein IDO may impart a protumorigenic skew (2). To investigate this hypothesis in an autochthonous lung tumor setting, we introduced \(\text{Ido}1^{-/-}\) (homozygous Idol-null) alleles (18) into the LSL-Kras\(^{G12D}\) mouse strain. \(\text{Ido}1^{-/-}\)Lox-Kras\(^{G12D}\) mice displayed significantly increased survival relative to Lox-Kras\(^{G12D}\) mice at 2 different multiplicities of Ad-Cre infection (Fig. 1A and B). Similar levels of Cre were present in the lungs of both strains at 0, 1, 3, and 7 days postinfection (Fig. 1C). Unexpectedly, histopathologic examination at 6 weeks revealed that the frequency of early precancerous lesions was actually about 3-fold higher in the \(\text{Ido}1^{-/-}\)Lox-Kras\(^{G12D}\) mice (Fig. 1D and E), substantiating...
that IDO deficiency does not interfere at the stage of Ad-Cre–mediated oncogenic RAS activation required to initiate these tumors (ref. 16; Supplementary Fig. S1A). While early tumorigenesis may be negatively impacted by IDO-mediated tryptophan catabolism, as previously proposed (19), this phenomenon was transient with the differential no longer significant by 12 weeks (Fig. 1E).

**IDO Deficiency Impairs Tumor Outgrowth and Vascular Development in the Lung**

To assess the impact of Idol loss on overt lung tumors, noninvasive micro-computed tomographic (CT) scans were conducted on groups of Lox-Kras\textsuperscript{G12D} and Idol\textsuperscript{−/−} Lox-Kras\textsuperscript{G12D} mice at 18 and 24 weeks following Ad-Cre administration (Fig. 2A),
Figure 3. IDO deficiency is associated with attenuated induction of IL-6 and MCP1. A, kynurenine levels in the lungs of Lox-KrasG12D and Ido1−/−Lox-KrasG12D mice at 0, 12, 19, and 26 weeks postinfection (n = 3) assessed by LC/MS-MS analysis and plotted as the means ± SEM. B and C, IL-6 and MCP1 levels in the lungs of Lox-KrasG12D and Ido1−/−Lox-KrasG12D mice at 0, 12, 19, and 26 weeks postinfection (n = 3) assessed by multiplexed cytokine bead immunoassay-based analysis and plotted as the means ± SEM with significance relative to baseline determined by one-way ANOVA with Dunn test (P < 0.05).

Semi-automated quantitative image analysis (20) was conducted on 3-dimensional (3D) reconstructions of the thoracic cavity excluding the heart to assess the combined tumor and vasculature volume within this space. Although lung tumor burden did increase progressively in both cohorts, it was significantly reduced in the Ido1−/−Lox-KrasG12D mice relative to the corresponding Idol-competent Lox-KrasG12D mice (Fig. 2B). Individual micro-CT scan images paired with 3D reconstructions of total chest space and functional lung volume visually highlight the difference in lung tumor burden between representative Ido1−/−Lox-KrasG12D and KrasG12D animals (Fig. 2A; Supplementary Videos). These results indicate that IDO deficiency mitigates overt lung tumor outgrowth, consistent with the increased survival exhibited by these mice.

Micro-CT analysis additionally revealed that the density of normal vasculature in the lungs of uninfected animals was substantially diminished in the Ido1−/−mice (Fig. 2A and B). Intriguingly, the difference in vascular density between IDO-deficient and IDO-competent cohorts was proportionately comparable with the difference in overt lung tumor burden at the 18- and 24-week time points (Supplementary Fig. S1B), suggesting an association between the extent of the underlying basal vasculature and the capacity of the lungs to support tumor formation. Immunofluorescent staining of blood vessels in the lungs confirmed the decrease in pulmonary vascular density in Ido1−/−animals (Fig. 2C). The area within the lungs occupied by vessels was reduced by about 1.6-fold in Ido1−/−animals (Fig. 2D), in line with the differential identified by micro-CT data analysis. Further analysis revealed that the reduction in vascular density occurred predominantly at the level of small- to medium-sized vessels, which were nearly twice as abundant in the wild-type (WT) animals, whereas there was little difference in the number of large vessels (Fig. 2E; Supplementary Fig. S1C).

IDO Promotes IL-6 Elevation during Lung Tumor Formation

In the lungs, IDO is highly responsive to pathogen or cytokine exposure (14, 15). To determine whether lung tumorogenesis also stimulates IDO, we compared steady-state levels of the tryptophan catabolite kynurenine at various times after KrasG12D activation. Although baseline levels of kynurenine in the lungs of uninfected Lox-KrasG12D mice were significantly higher than in their IDO-deficient counterparts (Fig. 3A), these levels remained constant during lung tumorogenesis (Fig. 3A). In contrast, a multiplexed analysis of inflammatory cytokines at 19 and 26 weeks revealed IL-6 to be elevated by about 25- and 68-fold, respectively, in lungs from tumor-bearing Lox-KrasG12D mice but only by about 1- and 3-fold in Ido1−/−Lox-KrasG12D mice (Fig. 3B). This finding was notable given the known tumor-promoting role of IL-6 in this model (21). Although not of the same magnitude, induction of CCL2/MCP1 [chemokine (C-C motif) ligand 2] was likewise attenuated in tumor-bearing Lox-KrasG12D mice lacking Ido1 (Fig. 3C). In contrast, Ido1 loss did not significantly affect the relative levels of IL-10, IFN-γ, TNF-α, or IL-12p70 (data not shown).

IDO Deficiency Impedes the Development of Pulmonary Metastases

Given the evidence that Ido1−/−mice are resistant to the outgrowth of primary lung tumors, we asked whether Ido1−/−animals might exhibit reduced susceptibility to pulmonary metastasis development as well. This question was investigated by orthotopic engraftment of mice with highly malignant 4T1 breast carcinoma cells, which metastasize efficiently to the lungs. Survival was increased significantly in Ido1−/−hosts compared with WT hosts after challenge with either a 4T1-luciferase–expressing subclone or with parental 4T1 cells, despite an overall shift in the curves (Fig. 4A and B). No difference in primary tumor growth rate was observed (Supplementary Fig. S2A and S2B), but metastatic lung nodules at necropsy were unambiguously less pronounced in Ido1−/−mice (Fig. 4C). Noninvasive micro-CT imaging also confirmed a marked reduction in metastatic burden in Ido1−/−mice (Fig. 4C), which was quantified by an ex vivo colony-forming assay (ref. 22; Fig. 4D). The metastasis differential was not attributable to reduced intravasation because the same numbers of tumor cells were present in peripheral blood samples from both strains (Fig. 4D). In contrast to lung,
Figure 4. IDO deficiency delays the development of pulmonary metastases. Kaplan-Meier survival curves for cohorts of WT and Ido1−/− mice following orthotopic engraftment of 1 × 10⁴ (A) 4T1-luc (n = 25) or (B) 4T1 (n ≥ 9) tumor cells. Significance was assessed by 2-group log-rank test at P < 0.05. The survival benefit observed in Ido1−/− mice was independently replicated at University of Maryland Baltimore County. (C) Staining of lungs with India ink and axial images from micro-CT scans depicting the difference in pulmonary metastasis burden between WT and Ido1−/− mice at 5 weeks following orthotopic 4T1 tumor cell engraftment. At 5 weeks following (D) orthotopic engraftment of 4T1 cells (n = 6) or (E) orthotopic engraftment of 4T1 cells and resection of the primary tumor at 18 days postengraftment (n ≥ 11), colony-forming assays were conducted to assess the relative tumor cell burden in the blood (neat) and lungs (1:1,000). Individual data points are graphed on a log scale scatter plot with the means ± SEM and significance assessed by 2-tailed Student t test at P < 0.05 (NS, not significant).
Figure 5. IDO deficiency is associated with attenuated induction of IL-6 during 4T1 tumor metastasis. A, evaluation of IDO1 protein levels by immunoprecipitation-Western blot analysis of lung tissue lysates from WT and Id01−/− mice following orthotopic engraftment of 4T1 tumor cells at the time points in weeks indicated above each lane. C, epididymis lysate positive control lane; M, molecular weight marker lane. B, evaluation of kynurenine levels by LC/MS-MS–based analysis of homogenized lung samples from WT and Id01−/− mice following orthotopic engraftment of 4T1 tumor cells at the time points in weeks indicted for each lane. Means ± SEM (n ≥ 6) are graphed with significance relative to baseline determined by one-way ANOVA with Dunn test (*, P < 0.05; **, P < 0.01). C, IL-6 level determinations from cytokine bead array immunoassay–based analysis of homogenized lung samples from WT and Id01−/− mice following orthotopic engraftment of 4T1 tumor cells at the time points in weeks indicted for each lane. Means ± SEM (n ≥ 3) are graphed with significance relative to baseline determined by one-way ANOVA with Dunn test (*, P < 0.05; **, P < 0.01).

**IDO Is Activated during Metastatic Lung Colonization and Potentiates IL-6 Induction**

In WT mice, IDO1 protein and kynurenine levels both increased in the lungs during 4T1 metastasis development, particularly at 5 and 6 weeks postengraftment (Fig. 5A and B). The principal source of IDO1 expression in this context appears to be the native stroma rather than the engrafted 4T1 tumor cells because no IDO1 protein was detectable in the lungs of Id01−/− mice (Fig. 5A), even at 7 weeks postengraftment when what higher at baseline in the Id01−/− lungs (Supplementary Fig. S2D).

no difference in metastatic burden was observed in liver, although the presence of 4T1 cells was also nearly too low to detect in this tissue (Supplementary Fig. S2C). Because excision of the primary tumor can alter immune-based effects on metastasis (23), we evaluated the metastasis burden in resected mice. Id01−/− mice continued to exhibit significant resistance to metastasis development (Fig. 4E), indicating that IDO-mediated support of metastatic development in lung is not dependent on the presence of the primary tumor. We also examined pulmonary VEGF levels but found that these increased comparably in both WT and Id01−/− lungs during metastasis development and were actually some-
IDO Drives Lung Cancer and Metastasis

The metastatic tumor burden was high. However, a weak but significant increase in kynurenine was observed in the lungs of Ido1−/− mice (Fig. 5B), suggesting that metastasis development may be associated with induction of an alternative mechanism of kynurenine production, such as IDO2 (24) or TDO2 (tryptophan 2,3-dioxygenase; ref. 25), either in conjunction with or in the absence of IDO1.

As in the Kras-driven primary lung tumor model, Ido1 competence in the pulmonary metastatic setting was linked to enhanced elevation of IL-6, with levels increasing up to 15-fold over baseline in WT animals (Fig. 5C). On the other hand, the IL-6 levels in Ido1−/− lungs remained about 2- to 4-fold over baseline even when evaluated at an extended time point to account for the differential in tumor burden (Fig. 5C). Thus, like the autochthonomous lung tumor studies, results from this lung metastasis model led us to infer a positive regulatory link between IDO and IL-6 production.

Direct interrogation of this hypothesis was carried out in a cell-based assay with known IDO inducers. Lipopolysaccharide (LPS) induced both IDO activity and IL-6 production in monocyctic U937 cells whereas IFN-γ on its own elicited little response but greatly elevated the level of IDO activity in combination with LPS that was mirrored by a comparable enhancement of IL-6 production (Fig. 6A). In both instances, inclusion of the competitive IDO-inhibitory compound MTH-tryptophan (8) significantly suppressed the observed increases in IDO activity as well as IL-6 production (Fig. 6A). MTH-tryptophan–mediated suppression of IL-6 induction was confirmed in a second monocytic cell line HL-60 (Fig. 6B). Likewise, siRNA-mediated interference with Ido1 gene expression also significantly suppressed IL-6 induction (Fig. 6C). Taken together, these results are consistent with our in vivo findings suggesting that IDO activity can potentiate the elevated production of IL-6.

### IDO Drives MDSC Expansion and Immunosuppressive Function

Studies in Il1r−/− (IL-1 receptor-nullizygous) mice have shown a crucial role for IL-6 in 4T1 pulmonary metastasis development (26). At the cellular level, IL-1β enhances development...
of tumor-promoting MDSCs with IL-6 serving as a critical downstream mediator of this process (26). Because Ido1 loss attenuated IL-6 induction and metastatic colonization in the lung, we hypothesized that MDSCs may be compromised at some level in tumor-bearing Ido1−/− mice. MDSCs isolated from WT and Ido1−/− mice did not differ phenotypically (Fig. 7A; Supplementary Fig. S3A); however, an early delay in the expansion of Gr1+CD11b+ cells in Ido1−/− mice, similar to that observed in Il1r−/− animals (26), was noted (Fig. 7B). Moreover, circulating MDSCs isolated from Ido1−/− hosts were functionally impaired in their ability to suppress T cells (Fig. 7C). We did not detect IDO1 protein in Gr1+CD11b+ cells...
IDO Drives Lung Cancer and Metastasis

obtained from tumor-bearing WT hosts (Supplementary Fig. S3B), consistent with the hypothesis that the observed functional impairment of MDSCs is a non–cell-autonomous effect of Ido1 deficiency in which IL-6 may act as a key intermediary.

IL-6 Is Critical to IDO-Driven MDSC Activity and Pulmonary Metastasis

To directly test the ability of IL-6 to functionally restore MDSC-suppressive activity in Ido1−/− mice, orthotopic tumors were established using 4T1-IL-6 cells (26), a 4T1 cell population engineered to constitutively express IL-6. MDSCs isolated from Ido1−/− mice engrafted with 4T1-IL-6 cells exhibited an elevated T-cell-suppressive activity similar to that of MDSCs isolated from WT hosts engrafted with parental 4T1 cells (Fig. 7D). Further enhancement of MDSC-suppressive activity could be achieved by engrafting 4T1-IL-6 cells into WT mice (Fig. 7D), indicating that the endogenous IL-6 levels stimulated by parental 4T1 tumor cells in WT animals were not fully saturating with regard to promoting MDSC suppressor function.

We next asked whether restoring IL-6 levels could also reverse the metastatic resistance exhibited by Ido1−/− mice. In the orthotopic setting, high levels of IL-6 produced in primary tumors formed by 4T1-IL-6 cells complicated the analysis by impairing the efficiency of pulmonary metastasis [possibly reflecting the recruitment of metastatic cancer cells back to IL-6-expressing primary tumors as documented previously (ref. 27)]. However, as our results in orthotopically engrafted mice had indicated that the Ido1 allelic status does not affect 4T1 intravasation, we reasoned that a valid assessment of the impact of Ido1 deficiency on pulmonary metastasis could be made by introducing the metastatic tumor cells directly into the circulation. Accordingly, we confirmed that intravenously engrafted Ido1−/− mice maintained their resistance to pulmonary metastasis formation, with the apparent mean metastatic tumor burden being 30.4- and 31.6-fold lower in Ido1−/− versus WT mice challenged with 4T1 and 4T1-IL-6 cells, respectively (Fig. 7E). The proportional increase in metastatic burden observed in the 4T1-IL-6 challenged cohorts is also in line with the proposed interpretation of the MDSC functional data that IL-6 is not being produced at saturating levels in the 4T1-challenged WT animals. Because of the significantly higher metastasis burden produced by 4T1-IL-6 cells, comparison of 4T1-IL-6-challenged Ido1−/− mice to 4T1-challenged WT mice yielded a differential in mean metastatic tumor burden of only 4.8-fold (Fig. 7E). Thus, IL-6 supplementation not only rescued WT levels of MDSC suppressor function in 4T1 tumor-challenged Ido1−/− mice but also markedly restored their susceptibility to pulmonary metastasis development.

DISCUSSION

The idea of immune escape as a “hallmark of cancer” (28, 29) represents a groundbreaking although still largely untested paradigm within the field of cancer biology. The presumption that tumors exploit IDO activity as a mechanism of immune escape, initially inferred from the pioneering studies on maternal immune tolerance of Munn and colleagues (30), has become increasingly accepted despite a fundamental deficit in genetic support for the role of IDO in tumor development. This study addresses this gap with direct genetic validation of the importance of IDO in well-established models of lung cancer and metastasis that offers novel insights into the impact of IDO on tumor pathogenesis. Moreover, these findings strongly encourage the prioritization of clinical investigations into the use of IDO pathway inhibitors for treating lung adenocarcinomas and pulmonary metastases where more effective modalities are urgently needed.

While IL-6 activity was not elevated in lung tissue beyond baseline levels during KRAS-driven lung tumor development, the observed reduction in pulmonary vascularization in Ido1−/− animals even before initiation of tumorigenesis implied that the loss of steady-state IDO in this context was sufficiently consequential to impact physiologic processes important to tumor outgrowth. Enhanced tumor vascularization has been reported in tumor xenograft models involving exogenous IDO overexpression (31,32), but our study is the first to identify a role for IDO in supporting vascular development under native physiologic conditions. Our findings likewise genetically establish the importance of IDO activity in nontumor cells for supporting pulmonary metastasis. In this manner, IDO activity may influence metastatic dissemination to tissues such as the lung where its expression is particularly robust. This may, however, be less relevant when IDO [or tryptophan 2,3-dioxygenase (ref. 25)] activity is substantially elevated within the tumor cells themselves (8, 33), enabling the malignancy to preemptively shape its surroundings through intrinsic tryptophan catabolism. As such, IDO activity that originates from stromal cells of the tumor microenvironment or from the tumor cells themselves may contribute to directing tumor outgrowth.

The positive association between IDO and IL-6 in lung tumorigenesis and metastasis was not necessarily anticipated, given that it runs counter to expectations based on IDO-mediated induction of liver-enriched inhibitory protein (LIP), a negative regulatory isoform of the Il6 gene expression promoting transcription factor C/EBPβ (24, 34). The precise regulatory impact of LIP on Il6 expression is not clear cut; however, insofar as other findings have indicated that LIP can interact with NF-κB to induce rather than limit Il6 transcription (35). Our findings are also consistent with evidence that a downstream product of IDO-mediated catabolism, kynurenic acid, can potentiate IL-6 production in the context of inflammation by signaling through the aryl hydrocarbon receptor (36). IL-6 is a pleiotropic cytokine that is widely implicated in supporting neoplastic outgrowth in the context of chronic inflammation (37). Clinically, IL-6 has been established as a marker of early relapse of resected lung tumors (38). Analyses of DNA polymorphisms in the IL-6 promoter region have identified positive correlations between IL-6 inducibility and lung cancer susceptibility in the context of concurrent inflammatory disease (39) as well as micrometastatic disease in patients with high-risk breast cancer (40). Functionally, IL-6 induction has been identified as an essential downstream component of RAS-induced tumorigenesis (41) that is directly linked to lung tumor development in the Lox-KrasG12D transgenic mouse model (21). Numerous other studies indicate that IL-6 can also contribute to tumor promotion by supporting angiogenesis and neovascularization of tumors (42, 43). Thus, biologically,
the epidemiologic and functional data for IL-6 are consistent with the tumor-promoting activity that we have ascribed to IDO through mouse genetics.

Tumor responses to IDO-inhibitory compounds require functional host immunity (5, 6, 8, 9), but the mechanisms through which IDO promotes immune escape have yet to be fully delineated. Connecting IL-6 to IDO provides valuable insight in this regard. IL-6 has previously been identified in the 4T1 metastasis model as critical to the induction of MDSCs, which act as potent inhibitors of antitumor immunity (44). MDSC accumulation is known to be driven by several factors that are produced by tumor cells and the tumor stroma, including the potent inflammatory mediators prostaglandin E2 and IL-1β (45–47). Genetic ablation of IL-1β signaling can affect both the early accumulation of MDSCs as well as their immunosuppressive capability (26), and IL-6 has been determined to be a downstream mediator for the effects of IL-1β on MDSC populations in tumor-bearing animals (26). In this context, our findings identify IDO as a key determinant of IL-6–elicited MDSC accumulation and suppressor activity. Interestingly, IL-1β may dynamically potentiate the contribution of IDO to IL-6 induction given that IL-1β may dynamically potentiate the contribution of IDO to IL-6 (NCI-Frederick, Frederick, MD). Administration of Ad-Ido1−/− mice to LSL-KrasG12D mice was generated through breeding of the 2 transgenic strains. Mating pairs of BALB/c and T-cell receptor (Tcr) transgenic DO11.10 BALB/c mouse (I-Ad–restricted, specific for chicken ovalbumin323–339) were obtained from The Jackson Laboratory. Mating pairs of Tcr transgenic Clone 4 BALB/c mice [H-2Kβ–restricted, specific to influenza hemagglutinin (HA) peptide518–526] and Tcr transgenic Tsi BALB/c mouse [I-Eβ–restricted, specific to HA peptide120–137] were provided by E. Fuchs (Johns Hopkins, Baltimore, MD). All procedures involving mice were approved by either the Lankenau Institute for Medical Research (LIRM, Wynnewood, PA) or University of Maryland Baltimore County (UMBC) Institutional Animal Care and Use Committee (IACUC).

**Micro-CT Scanning**

Three-dimensional micro-CT images were acquired from anesthetized mice using an Impek Micro-CT scanner operated at 40-kVp, 500-μA, 250-millisecond per frame, 5 frames per view, 360 views, and 1-degree increments per view. Contiguous axial DICOM-formatted images through each mouse thorax, with voxels of dimensions 91 μm × 91 μm × 91 μm were compiled into 3D format using Amirra v5.1 software and normalized to Hounsfield units. Using the segmentation editor, manual selections of the chest cavity minus the heart were conducted on every other slice followed by interpolation of these selections. Magic wand tool selection was conducted at the threshold range defining air (determined to be between −750 and −350) to define the functional lung volume, which was automatically subtracted from the total chest space to identify the volume representing vasculature and tumors (20).

**4T1 Tumor Cell Metastasis**

Parental 4T1 mouse mammary carcinoma cells and 4T1-derived cell lines expressing luciferase (4T1-luc) or mouse Il6 (4T1–IL-6) were maintained as described (5, 22, 26). Primary tumor growth was monitored by caliper measurements of orthogonal diameters. Tumor volume was calculated using the formula for determining a prolated ellipsoid [l × w × h/2 = 0.52 lwh], where d is the shorter of the 2 orthogonal measurements. To enhance visualization of metastatic nodules, lungs were infused with India ink dye, washed, and bleached in Fekete’s solution. The enolomass assay to assess metastatic burden was conducted as described (22).

**Real-time PCR**

Lung DNA was analyzed by Real Time-PCR containing SYBR green PCR master mix (Applied Biosystems) and primers to amplify Cre (5′-GGAGCAGCGGCGGACA-3′ and 5′-GCCACGCTTGCGTCTAC-3′) and endogenous mouse Cdb1 (5′-TGCGCCAAGGATGTAAGAACA-3′ and 5′-CATTGTTGTGACATCATCACA-3′). Assays were conducted in quadruplicate, and relative quantification of the viral Cre gene present in lung tissue was calculated using the comparative threshold cycle (Ct) method (User Bulletin 2, Applied Biosystems) normalizing the target Ct values to the internal housekeeping gene (Cdb1).

**Histology**

Tissues were isolated and fixed in 10% neutral-buffered formalin or 4% paraformaldehyde, sectioned, and stained for histopathologic analysis with hematoxylin and eosin using standard methods. For immunofluorescent staining, 4-μm paraffin sections were deparaffinized in xylene and rehydrated with a graded alcohol series. Following antigen retrieval (vector), sections were washed and placed in 0.1% Triton for 10 minutes. Tissue was blocked in 40 μg/mL goat anti-mouse IgG-Fab (H+L) (Jackson ImmunoResearch) followed by activation of the latent KrasG12D allele in lungs of LSL-KrasG12D transgenic mice (referred to as L-AvrKrasG12D mice; ref. 16) was carried out as described (52). Doubly mutant Ido1−/− LSL-KrasG12D mice were generated through breeding of the 2 transgenic strains. Mating pairs of BALB/c and T-cell receptor (Tcr) transgenic DO11.10 BALB/c mouse (I-A^q–restricted, specific for chicken ovalbumin323–339) were obtained from The Jackson Laboratory. Mating pairs of Tcr transgenic Clone 4 BALB/c mice [H-2Kβ–restricted, specific to influenza hemagglutinin (HA) peptide518–526] and Tcr transgenic Tsi BALB/c mouse [I-Eβ–restricted, specific to HA peptide120–137] were provided by E. Fuchs (Johns Hopkins, Baltimore, MD). All procedures involving mice were approved by either the Lankenau Institute for Medical Research (LIRM, Wynnewood, PA) or University of Maryland Baltimore County (UMBC) Institutional Animal Care and Use Committee (IACUC).
10% normal goat serum (Jackson ImmunoResearch). Rabbit anti-
mouse caveolin-1 (1:200; Cell Signaling) was incubated overnight
at 4°C. Sections were washed and incubated with goat anti-rabbit
Cy3 (1:200; Jackson ImmunoResearch). Tissues were mounted using
Prolong Gold with DAPI (Invitrogen). To quantitate the blood vessel
areas present within defined fields of caveolin-1–stained lung sam-
ple images were acquired per mouse from 3 WT and 5 Idel−/− mice.
Vessel boundaries were identified by caveolin-1 staining, and the area
of every vessel within each field was determined using AxioVision
Release 4.6 software.

**Immunoprecipitation–Western Blot Analysis**

Immunoprecipitation of IDO1 protein from mouse lung tissue with
purified rabbit polyclonal antibody (7) followed by Western
blotting–based detection with rat monoclonal antibody (clone
mIDO-48; BioLegend) was carried out as described (9).

**Flow Cytometry for Cytokine and Cell Analysis**

Flow cytometric data were acquired on a FACSCanto II or Cyan
ADP flow cytometer and analyzed using FACSDIVA (BD Biosciences)
or Summit v.4.3.02 (Beckman/Coulter) software. Multiplexed cytokine
analysis was conducted using the Inflammation Bead Array (BD Bio-
sciences). Lung homogenates were centrifuged and supernatant added
to the array according to the manufacturer’s instructions. Flow
cytometric analysis of MDSCs harvested from digested lung
samples or from blood was conducted with the following antibodies
as indicated: Gr1-FTTC, Ly6G-PE, Ly6C-FFTC, and CD11c (1L-4-Ro)-PE
(BD Biosciences); CD11b-PacB, CD11c-PE, and F4/80-PE (BioLegend);
Ly6C-PerCP (eBioscience); and arginase and iNOS (BD Transduction
Labs). Second step goat anti-mouse IgG-Alexa 647 for arginase and
inducible NO synthase (iNOS) was from Invitrogen. Isotype control
antibodies were from BD Biosciences.

**Kynurenine Assay**

Lungs were homogenized in PBS containing dithiothreitol (DTT)
and protease and phosphatase inhibitors (1:3 wt/vol). Deproteinized
lysates were analyzed by high-performance liquid chromatography
(HPLC) coupled to electrospray ionization liquid chromatography/
tandem mass spectroscopy (LC-MS-MS) analysis as described (9).

**Cell Culture**

U937 and HL-60 monocytic cell lines (American Type Culture Col-
lection) were expanded for frozen storage after receipt and freshly
thawed cells cultured in Dulbecco’s Modified Eagle’s Media + 10% FBS
were used at early passage for experiments. No additional authen-
tication was conducted by the authors. Twenty-four–hour treatment
of cells with LPS (100 ng/mL; Sigma) and/or IFN-γ (100 ng/mL;
R&D systems) was carried out in triplicate on 1 × 10^6 cells per well
in a 96-well dish. MTH-Trp (methylthiohydantoin-DL-tryptophan;
100 μmol/L; Sigma) was also included at the time of induction
as indicated. Kynurenine and IL-6 levels in the supernatant were
carried out with goat anti-rabbit IgG, horseradish peroxidase (HRP)-
linked secondary antibody (catalog no. 7074; Cell Signaling) using
the SuperSignal West Femto Chemiluminescent substrate (Thermo
Scientific).

**T-cell Suppression Assay**

MDSC-suppressive activity was measured as previously described
(53) using transgenic splenocytes and their cognate peptides in the
presence of 25 Gy–irradiated, blood-derived MDSCs from 4T1
mouse tumor-bearing mice. HA118–126, HA110–119, and Ova323–339 peptides
were synthesized in the Biopolymer Core Facility at the University of
Maryland, Baltimore, MD. ELISA duo set mAbs for mIL6 were from
R&D Systems. Monoclonal antibody Vβ8.1,8.2-PE was from BD
PharMingen.

**Disclosure of Potential Conflicts of Interest**

G.C. Prendergast, A.J. Muller, and J.B. DuHaddaway declare a poten-
tial conflict of interest with regard to IDO due to intellectual prop-
erty, financial interests, grant support, and consultancy roles with
New Link Genetics Corporation, which is engaged in the clinical
development of IDO inhibitors for the purpose of treating cancer
and other diseases. R. Metz is an employee of New Link Genetics Cor-
poration as Director of Research and has financial and intellectual
property interests in the company. No potential conflicts of interests
were disclosed by the other authors.

**Authors’ Contributions**

Conception and design: C. Smith, S. Ostrand-Rosenberg, G.C. Prendergast, A.J. Muller
Acquisition of data (provided animals, acquired and managed
Analysis and interpretation of data (e.g., statistical analysis,
Writing, review, and/or revision of the manuscript: C. Smith, D.W. Beury, A.P. Soler, L.D. Laury-Kleintop, L. Mandik-Nayak, R. Metz, S. Ostrand-Rosenberg, G.C. Prendergast, A.J. Muller
Administrative, technical, or material support (i.e., reporting or
organizing data, constructing databases): C. Smith, J. Boulden, A.P. Soler, S. Ostrand-Rosenberg
Study supervision: C. Smith, S. Ostrand-Rosenberg, A.J. Muller, G.C. Prendergast

**Acknowledgments**

The authors thank Gwen Guillard for tissue sectioning and histology
and Lingling Yang for preliminary studies on MDSCs in IDO-
deficient mice.

**Grant Support**

A.J. Muller is the recipient of grants from Susan G. Komen for
the Cure and the W.W. Smith Foundation. G.C. Prendergast is the
recipient of NIH grants CA105942, CA159373, and CA159315 with
additional support from New Link Genetics Corporation, the Sharpe-
Strumia Foundation, the Lankenau Medical Center Foundation, and
the Main Line Health System. S. Ostrand-Rosenberg is the recipient
of NIH grants RO1CA115880, RO1CA84232, and RO1GM021248.
C. Smith is the recipient of a postdoctoral fellowship through the
Department of Defense Breast Cancer Research Program. D. Beury is
the recipient of a predoctoral fellowship through the Department of
REFERENCES


IDO Drives Lung Cancer and Metastasis


Supplementary Figure S1. (A) Confirmation of the presence of the recombined $\text{Lox-Kras}^{G12D}$ allele in Ad-cre infected mice with lung tumors. PCR-based analysis of genomic DNA prepared from lung tissue from $\text{LSL-Kras}^{G12D}$ and $\text{Ido1}^{-/-}$ $\text{LSL-Kras}^{G12D}$ mice prior to infection (–) and from 2 mice from each group at 26wk postinfection (+). The recombined $\text{Lox-Kras}^{G12D}$ knockin (KI) allele yields a product of 315 bp evident only in the post-infection lanes, while the opposite, unmodified (WT) $\text{Kras}$ allele yields a product of 285 bp present in every lane. The silenced, non-recombined $\text{LSL-Kras}^{G12D}$ knockin allele is too large to be detected in this assay. The marker (M) is HaeIII digested $\varphi$X174 phage DNA. (B) The difference in tumor and vasculature volumes...
between mice with and without IDO is proportionately similar even prior to the onset of tumor development. To graphically demonstrate the proportionality of the differences in pulmonary tumor and vasculature volumes between $LSL-Kras^{G12D}$ and $Ido1^{-/-}$ $LSL-Kras^{G12D}$ mice at the 0, 18 and 24 week time points, the data presented in Figure 2B are plotted on a log scale. The data are graphed as a scatter plot with bars representing the means ± SE. The fold difference ($\Delta$) between the mean calculated tumor and vasculature volumes for the two groups at each time point is included at the bottom of the graph. (C) Vascular density is reduced in the lungs of $Ido1^{-/-}$ mice. Lung tissue sections from 5 WT and 5 $Ido1^{-/-}$ mice were stained with anti-caveolin-1 antibody to visualize blood vessels by immunofluorescence. Four images per tissue section were acquired and area measurements of every blood vessel within each field were recorded using AxioVision Release 4.6 software. All of the area measurements were tallied and plotted sequentially in ascending order from smallest to largest with vessel areas graphed on a log scale. As delineated in the segregated presentation of these data in Fig. 2E, the differential in vessel density apparent from this graph is due almost entirely to a reduced number of medium to small sized vessels in the lungs of $Ido1^{-/-}$ mice while the number of large vessels (>5,000 $\mu m^2$) is nearly the same as in the WT mice.
Supplementary Figure S2. (A,B) Primary 4T1 tumor growth is unaffected in Ido1−/− mice. WT and Ido1−/− mice received orthotopic grafts of (A) 4T1-luc (N = 20) or (B) 4T1 (N = 5) cells. Beginning at approximately 14 days, when a palpable tumor mass had become apparent, caliper measurements were made on a weekly basis to calculate primary tumor volumes. The data are plotted as means ± SE. Measurements for WT mice challenged with 4T1 cells at 42 days were not collected due to metastasis-associated mortality in this group. (C) Ido1−/− mice exhibit no demonstrable resistance to 4T1 liver metastasis formation. At 6 weeks following orthotopic injection of 4T1-luc cells into WT and Ido1−/− hosts (N = 5 per group), colony forming assays were performed to assess the relative tumor cell burden in the liver. Individual data points are graphed as a scatter plot on a log scale together with the means ± SE. Because the data are plotted on a log scale, points with a value of 0 are not represented in the scatter plot.
but were included in computing the means. (D) VEGF is induced to similar levels in WT and $Ido1^{-/-}$ mouse lungs in response to 4T1 metastases. Mouse VEGF analysis was performed by the University of Maryland Cytokine Core Laboratory. Measurements of VEGF levels in homogenized lung samples from WT and $Ido1^{-/-}$ mice following orthotopic engraftment of 4T1 tumor cells at the time points in weeks indicted for each lane were assessed by two-antibody ELISA using biotin-streptavidin-peroxidase detection and are graphed as the means ± SEM ($N \geq 4$).
**Supplementary Figure S3.** (A) Phenotypic characterization reveals no demonstrable differences between MDSCs from WT and Ido1<sup>−/−</sup> mice. BALB/c strain WT and Ido1<sup>−/−</sup> mice were inoculated in the abdominal mammary gland with 10<sup>5</sup> 4T1 mammary carcinoma cells. MDSCs were harvested from the blood when WT and Ido1<sup>−/−</sup> mice had primary tumors that were not significantly different in size (12.2 ± 1.36 and 11.5 ± 0.4 mm in diameter, respectively). Red blood cells were removed by lysis and the remaining leukocytes were stained with mAbs to Gr1 and CD11b, or with mAbs to CD11b, Ly6C, Ly6G, and either arginase I, iNOS, CD115, F4/80, IL-4Rα and their respective isotype control mAbs, or with DCFDA to detect ROS. Gated CD11b<sup>+</sup>
cells were analyzed for Ly6C and/or Ly6G expression. Granulocytic (PMN) and monocytic (MO) MDSC were identified as per Youn et al. (J. Immunol. 2008, 18:5791-802) as CD11b⁺Ly6G⁺Ly6C⁻ or CD11b⁺Ly6G⁻Ly6C⁺ cells, respectively. Flow cytometry dotplots and histograms show MDSC from representative individual mice; graphs depict the average percent Gr1⁺CD11b⁺ cells or average mean channel fluorescence (MCF) for three mice per group. The values for total MDSC (Gr1⁺CD11b⁺) and for MO and PMN MDSC for iNOS, arginase, CD115, F4/80, IL-4Rα, and ROS are not statistically significantly different between MDSC from WT and Ido1⁻/⁻ mice (Student’s two-tailed t test with equal variance). (B) MDSCs from 4T1 tumor bearing mice lack detectable IDO1 expression. Western blot analysis using antibodies to IDO1 (top panel) and β-actin (bottom panel; loading control) with each lane individually labeled at the top. (Lanes 1,2) purified IDO1 protein for size confirmation with the adjacent lane left blank to avoid spillover contamination, (Lane 3; positive control) IFNγ-induced expression of IDO1 in OCM-3, a human melanoma cell line, (Lane 4; negative control) CD4 T cells lacking IDO1 expression, (Lane 5,6; experimental) MDSC isolated from 4T1 or 4T1-IL6 tumor-bearing mice and stimulated with IFNγ for 24 hours prior to analysis.